Building on this evidence, PRAISE-U presents an opportunity to revolutionise prostate cancer screening methodologies by adopting a risk-based approach that aligns with European Union member states, as well as promoting positive change towards current awareness around PSA testing by incorporating the learnings of the last 30 years of research. This evidence concerns the gene KLK3 and Familial prostate cancer.